There are three stages of clinical trials prior to FDA approval – Phase I, II and III. Phase III trials are the most expensive but also most likely to be funded if promising as these programs have generally been in-licensed by a large pharmaceutical company by this stage.
Phase I and Phase II trials are typically funded by VC firms, private investors, and sometimes sponsored by biotech/pharmaceutical companies. These are highly competitive monies to obtain and often consider many factors beyond pure science. While grants may be available, these are generally on a cost-sharing basis which requires scientists to go out and raise the remainder of funds from other sources. The end result is a bottleneck in funding for promising treatments and a limited number of sources outside traditional industry channels.
Give To Cure was founded by two healthcare entrepreneurs passionate about finding cures and shifting the paradigm shift in the development of life-saving treatments. The need for Give to Cure was identified from within industry. Today, the Give To Cure team comprises of over 20 years experience in healthcare and biotech, regional and national ad campaigns for Fortune 500 companies and start-up and project launches. We are working with some of the world’s leading scientists, business executives, artists, and civil servants – all united by the fact that we all know that we can make a difference together.
Give to Cure is a 501 (c) 3 non-profit organization. EIN: 46-1885780
Board Members: Louis G. Reese IV, President; William Kendall, Treasurer; Mei Mei Hu, Secretary.
Mission Statement: The objects and purposes of the Corporation shall include, but not be limited to: (i) raising awareness of, and educating the public about, diseases for which there are cures or effective treatments that are not available on a wide scale; (ii) creating a worldwide network of supporters dedicated to the fight against such diseases; and (iii) disbursing grants in support of clinical trials for drugs to treat and eradicate such diseases.